Oxycodone

THURSDAY, Dec. 19, 2024 -- After years of decline, U.S. life expectancy is finally on the rise again for the first time since 2019, new government research shows. This turnaround was driven in part by a decline in drug overdose deaths, which had risen dramatically as a result of the opioid epidemic, according to a second report from the U.S. Centers for Disease Control and Prevention. That includes the first reduction in OD deaths caused by powerful synthetic opioids like fentanyl and tramadol, researchers said. “The age-adjusted rate for drug overdose deaths involving synthetic opioids other than methadone decreased from 2022 to 2023, the first such decrease since the large increases that began in 2013,” concluded the research team led by Matthew Garnett , an injury epidemiologist and statistician with the CDC’s National Center for Health Statistics (NCHS). “The rate also decreased for deaths involving natural and semisynthetic opioids and heroin between 2022 and 2023,” the team added. Life expectancy at birth in 2023 was 78.4 years for the total population, an increase of 0.9 years from 77.5 in 2022, CDC researchers reported. For men, life expectancy increased 1 year, from 74.8 in 2022 to 75.8 in 2023. Meanwhile, women saw a 0.9-year increase, from 80.2 in 2022 to 81.1 in 2023. “From 2022 to 2023, age-adjusted death rates decreased for 9 of the 10 leading causes of death,” wrote the life expectancy research team led by Elizabeth Arias , a health scientist with the NCHS. Deaths due to heart disease, accidental injury, stroke, respiratory disease, Alzheimer’s disease, diabetes, kidney disease, liver disease and COVID-19 all fell significantly between 2022 and 2023, researchers found. The rate of cancer deaths also went down, but not significantly, the report says. The end of the pandemic likely contributed to the increase in life expectancy, researchers said. “The most notable change was for COVID-19, which dropped from the 4th leading cause in 2022 to the 10th leading cause in 2023,” the researchers wrote. Overall, COVID deaths decreased more than 73% between 2022 and 2023, falling from 44.5 deaths to 11.9 deaths per 100,000, researchers said. A decrease in drug OD deaths also contributed to improved life expectancy. The rate of drug overdose deaths fell from 32.6 per 100,000 in 2022 to 31.3 per 100,000 in 2023, researchers said. Drug OD deaths are considered accidental injury deaths. These results jibe with statistics released last week by the CDC, which reported that drug OD deaths had decreased 17% between July 2023 and July 2024. However, the OD death rate is still 3.5 times what it was in 2003, when 8.9 people for every 100,000 died by drug overdose. Drug OD deaths related to synthetic opioids declined by 2.2% between 2022 and 2023, results show -- the first significant decline in OD deaths related to synthetic opioids like fentanyl since 2003, researchers added. Drug overdose deaths related to natural opioids like morphine, oxycodone and hydrocodone also declined 17.1%, between 2022 and 2023, and OD deaths caused by heroin decreased 33.3%. However, OD death rates for cocaine increased by 4.9% between 2022 and 2023, and OD deaths from stimulants like methamphetamine increased by 1.9%, researchers said. Lastly, infants did not seem to benefit from the declining death rates, researchers found. “The infant mortality rate of 560.2 infant deaths per 100,000 live births in 2023 was not significantly different from the rate in 2022,” the researchers wrote. The ten leading causes of infant death in 2023 -- birth defects, low birth weight, sudden infant death syndrome, unintentional injuries, maternal complications, bacterial sepsis of newborn, cord and placental complications, respiratory distress of newborn, intrauterine hypoxia and birth asphyxia, and diseases of the circulatory system -- accounted for more than 65% of all infant deaths, researchers concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024年12月13日—15日，2024中华医学会肿瘤学大会支持与康复治疗分会场在沈阳皇朝万鑫酒店6号会议厅成功召开。中华医学会肿瘤分会委员兼支持与康复治疗学组组长沈赞教授、中国医科大学附属第一医院刘云鹏教授、中国医科大学附属第一医院曲秀娟教授担任分会场的大会主席，上海交通大学医学院附属仁济医院王理伟教授、中国医科大学附属盛京医院王玉梅教授、中国医科大学附属盛京医院张晓晔教授担任大会主持。会议内容吸引了大批有志于肿瘤支持与康复治疗的专家和医生参会，同时邀请多位肿瘤领域知名专家带来癌痛患者全程管理新进展、安宁疗护同情默应、肿瘤患者全程康复管理实践与研究、中医在肿瘤患者康复中的应用、睡眠与肿瘤患者的康复等肿瘤支持与康复治疗相关最前沿研究报告，多位学术大咖共聚一堂各抒己见，内容丰富，精彩纷呈。 大会致辞 刘云鹏 教授 中国医科大学附属第一医院 专家授课 《癌痛患者全程管理新进展》 沈赞 教授 上海市第六人民医院 会议现场 癌痛药物治疗策略亟待提升，氢吗啡酮填补临床空白 沈赞教授作了《癌痛患者全程管理新进展》的专题学术报告，就当前癌痛治疗现状和NCCN指南在癌痛治疗中新的修改内容做了详细介绍，同时针对癌痛全程管理领域中滴定、维持治疗、阿片类药物不良反应防治等领域中涌现出的新药品如盐酸氢吗啡酮缓释片（商品名称：锐宁®）、注射用福沙匹坦双葡甲胺（商品名称：安福希®）等从临床研究、临床营养和药物未来前景等方面做了细致阐述。 阿片类药物为癌痛全程管理的基础用药，传统的治疗药物以吗啡、羟考酮口服即释、缓释制剂以及芬太尼透皮贴为主，近年来国内涌现新剂型及新品种较少，氢吗啡酮为其中突出代表。氢吗啡酮是一种半合成的阿片类镇痛药，主要作用于μ阿片受体，其口服效力约为吗啡的5倍，胃肠外途径给药时其镇痛药效约是吗啡的8-10倍，起效快，主要代谢产物无活性，不良反应少，是众多指南共识推荐的中重度癌痛治疗一线用药。目前，该活性成分国内有注射液、缓释片两种制剂获批上市，氢吗啡酮的上市正在填补国内空白，为临床使用带来更多便利性，为癌痛患者带来新曙光！ 盐酸氢吗啡酮缓释片作为宜昌人福药业独家上市的药品，是国内首个24小时长效口服阿片类缓释制剂，相较于临床常用的吗啡和羟考酮的口服缓释制剂更加贴合NCCN指南癌痛管理的5A目标。它采用独特的口服渗透泵缓释技术（Osmotic Release Oral System，OROS），可提供24小时持久镇痛，一天仅需口服一次，患者依从性更高，且释药呈零级动力学，不受介质环境影响，患者血药浓度更加平稳，因为释药口细小和悬液的黏度高，很难用针头或口吸的方法达到滥用的目的，具有防滥用的特性。且国谈医保定价比现有的同类药物价格更低，能进一步降低患者的经济负担，提升药物的临床可及性！ 本次大会为临床医生带来了肿瘤支持与康复治疗最前沿的学术资讯，同时也为癌痛全程管理提供了更多专业、规范的治疗建议，其宗旨是促进国内肿瘤支持与康复治疗领域的学术交流和技术进步，提升我国肿瘤支持与康复治疗的管理水平，为癌痛患者带来更多希望！ （来源：《肿瘤瞭望》编辑部） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。